Abstract 338P
Background
Cancer development is aggravated by a rare population of cells, termed cancer stem cells (CSCs), that uniquely initiates and sustains the disease. Although CSCs can orchestrate the immune systems in favour of tumor, the detailed mechanisms underlying their immunomodulatory effects remain elusive. Recent reports indicate the contribution of exosomes, secreted from various cells, as mediators of cell-to-cell communication and also as a mediator of immune modulation in the tumor microenvironment.
Methods
Breast CSCs (bCSCs) were purified from breast cancer cell lines and human breast tumor tissues following which CSC-derived exosomes (CDEs) were isolated. Peripheral blood mononuclear cells were isolated from the blood of healthy donors and breast cancer patients, co-cultured with CDEs, and T regulatory (Treg) cell generation was evaluated.
Results
We found that bCSCs are able to generate CD4+CD25+FOXP3+ Treg cells having suppressive activity. Our search for the underlying mechanism revealed for the first time that bCSC-secreted exosomes contain FOXP3 protein that uniquely initiates acquisition of Treg characteristics in the infiltrating T lymphocytes. Exosomes from FOXP3-ablated bCSCs failed to augment Treg cell generation indicating the requirement of bCSC-gifted FOXP3 in Treg generation. Interestingly, perturbation of transcription or translation in T naïve cells significantly decreased CDE-augmented FOXP3 level signifying that CDE-FOXP3 utilizes the transcription and translational machineries of T naïve cells to induce Treg cell generation. In fact, exosome-shuttled FOXP3 binds to the CNS2 region of the Foxp3 promoter in T lymphocytes, thus resulting in a sustained expression of FOXP3 and further leading to induction of other genes of Foxp3 interactome, thereby phenotypically converting the T cells to Treg cells.
Conclusions
Collectively our data demonstrates that bCSC-shed exosomal FOXP3 plays an important role in procreation of Treg cells within the tumor microenvironment thus leading to tumor-induced immune suppression. Breaching the deadly-liaison between them might be a promising strategy for breast cancer therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Prof. Tanya Das, Professor, Division of Molecular Medicine, Bose Institute.
Funding
Department of Science and Technology, Govt. of Inda Council of Scientific & Industrial Research (CSIR), Govt. of India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract